However, approximately one-half of patients with CBF-AML are still not cured, there is a need for markers to identify patients unlikely to respond to current treatment and to develop novel therapeutic approaches based on a better understanding of the pathophysiology of the disease35. Here, CEBPZ is linked to acute myeloid leukemia.